A quaternary ammonium salt of formula wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from an optionally substituted alkyl, alkenyl or aryl group having less than 8 carbon atoms and R.sup.5 is hydrogen or an optionally substituted hydrocarbyl group.

##STR00001##

A quaternary ammonium salt of formula wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from an optionally substituted alkyl, alkenyl or aryl group having less than 8 carbon atoms and R.sup.5 is hydrogen or an optionally substituted hydrocarbyl group.

##STR00001##

The present disclosure provides a versatile process for producing valuable renewable hydrocarbons from triglyceride containing feedstock. The triglyceride containing feedstock is first split to provide a mixture containing fatty acids, glycerol and water, from which a phase separation provides an oily phase, and an aqueous phase. The oily phase containing fatty acids is subjected to fractionation, whereby specific fractions may be refined to products with controlled hydroprocessing. Products may contain paraffinic renewable aviation fuel components, paraffinic renewable base oil, renewable paraffinic diesel fuel components, renewable paraffinic technical fluid, or any combination thereof.

The present disclosure provides a versatile process for producing valuable renewable hydrocarbons from triglyceride containing feedstock. The triglyceride containing feedstock is first split to provide a mixture containing fatty acids, glycerol and water, from which a phase separation provides an oily phase, and an aqueous phase. The oily phase containing fatty acids is subjected to fractionation, whereby specific fractions may be refined to products with controlled hydroprocessing. Products may contain paraffinic renewable aviation fuel components, paraffinic renewable base oil, renewable paraffinic diesel fuel components, renewable paraffinic technical fluid, or any combination thereof.

Disclosed are preparation of zinc linolenate, and application thereof in preparing an anti-Helicobacter pylori drug. Zinc chloride is dissolved in sterile water, and the zinc chloride solution is heated and activated in a reactor kettle, and then naturally cooled to room temperature; 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, N-hydroxysulfosuccinimide sodium salt and linolenic acid are dissolved in an EMS solvent and activated in nitrogen gas; the activated zinc chloride and the activated linolenic acid are heated and reacted, then left for standing after the reaction is finished; a dialysis bag is used to perform dialysis in pure water until the pure water is clear and transparent; and a vacuum freeze dryer is used to perform drying, and zinc linolenate is obtained. The present invention successfully prepares zinc linolenate, with high yield, and the zinc linolenate has a good Helicobacter pylori inhibiting effect.

Disclosed are preparation of zinc linolenate, and application thereof in preparing an anti-Helicobacter pylori drug. Zinc chloride is dissolved in sterile water, and the zinc chloride solution is heated and activated in a reactor kettle, and then naturally cooled to room temperature; 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, N-hydroxysulfosuccinimide sodium salt and linolenic acid are dissolved in an EMS solvent and activated in nitrogen gas; the activated zinc chloride and the activated linolenic acid are heated and reacted, then left for standing after the reaction is finished; a dialysis bag is used to perform dialysis in pure water until the pure water is clear and transparent; and a vacuum freeze dryer is used to perform drying, and zinc linolenate is obtained. The present invention successfully prepares zinc linolenate, with high yield, and the zinc linolenate has a good Helicobacter pylori inhibiting effect.

Provided is a free-polyunsaturated-fatty-acid-containing composition that has a total metal content of 0.1 ppm or less and that comprises at least one free polyunsaturated fatty acid having 20 or more carbon atoms, in an amount that is at least 80.0% of the amount of fatty acids in the composition; and a method for manufacturing a free-polyunsaturated-fatty-acid-containing composition, comprising: providing a raw material composition containing at least one polyunsaturated fatty acid having 20 or more carbon atoms; performing a hydrolysis treatment on a reaction solution prepared by combining the provided raw material composition, a lower alcohol, water having a total metal content of 0.01 ppm or less, and an alkali catalyst; and limiting the contact between the reaction composition and the metal after the hydrolysis treatment so that the product T [cm.sup.2×days] of the contact surface area [cm.sup.2] per 1 g and the contact time [days] between the composition and the metal is 100 or less.

Provided is a free-polyunsaturated-fatty-acid-containing composition that has a total metal content of 0.1 ppm or less and that comprises at least one free polyunsaturated fatty acid having 20 or more carbon atoms, in an amount that is at least 80.0% of the amount of fatty acids in the composition; and a method for manufacturing a free-polyunsaturated-fatty-acid-containing composition, comprising: providing a raw material composition containing at least one polyunsaturated fatty acid having 20 or more carbon atoms; performing a hydrolysis treatment on a reaction solution prepared by combining the provided raw material composition, a lower alcohol, water having a total metal content of 0.01 ppm or less, and an alkali catalyst; and limiting the contact between the reaction composition and the metal after the hydrolysis treatment so that the product T [cm.sup.2×days] of the contact surface area [cm.sup.2] per 1 g and the contact time [days] between the composition and the metal is 100 or less.

Provided is a novel nanoparticle, a contrast agent for magnetic resonance imaging containing the same, and a zwitterionic ligand compound used in production of the nanoparticle. The contrast agent for MRI of the present invention can be suitably used as a contrast agent for MRI in a medical field. The nanoparticle and the zwitterionic ligand compound of the present invention are applicable to various pharmaceutical compositions and the like, including a contrast agent for MRI, and can be used widely in the fields of pharmaceuticals, biotechnology, and the like, including various diagnosis methods and examination reagents.

Provided is a novel nanoparticle, a contrast agent for magnetic resonance imaging containing the same, and a zwitterionic ligand compound used in production of the nanoparticle. The contrast agent for MRI of the present invention can be suitably used as a contrast agent for MRI in a medical field. The nanoparticle and the zwitterionic ligand compound of the present invention are applicable to various pharmaceutical compositions and the like, including a contrast agent for MRI, and can be used widely in the fields of pharmaceuticals, biotechnology, and the like, including various diagnosis methods and examination reagents.